Clinical trial NCT06133270: A First Human Dose Study Investigating Safety and Concentration of Study Medicine in the Blood Following Once Daily Oral Dosing of NNC0560-0004 in Healthy Adults.
Official title: A Phase I, Randomised, Double Blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Once-daily Oral Doses of NNC0560-0004 in Healthy Humans, With an Additional Open Label Single Dose Cohort of CYP2D6 Poor Metabolizers.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Volunteers - Liver Diseases
Lead sponsor: Novo Nordisk A/S
Sponsor class: INDUSTRY
First posted: 2023-11-15
Enrollment: 51
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In this trial, medicine NNC0560-0004 given in capsule form will be compared to placebo in healthy volunteers.

Participants will either get NNC0560-0004 or placebo. Which treatment they get is decided by chance.

This is a first in human trial, which means that this is the first time that NNC0560-0004 is given to humans.

The study will last for about two weeks plus the screening period (approximately 42 days) which in all is about 8 weeks.

Women must be of non-childbearing potential thus you cannot take part if you are pregnant, can become pregnant, breast-feeding or plan to get pregnant during the study period.


Eligibility criteria: Key inclusion criteria:

1. Female, of non-childbearing potential, or male, both genders aged 18-55 years (both inclusive) at the time of signing informed consent.
2. Body Mass Index (BMI) between 18.5 and 29.9 kg/m\^2 (both inclusive) at screening.
3. Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests including inflammatory markers performed during the screening visit, as judged by the investigator
4. CYP2D6 phenotype:

   1. For Part A and Part B: ultra-rapid (from cohort A3 forward and B1 forward), normal or intermediate CYP2D6 function
   2. For Part C: CYP2D6 Poor Metaboliser function

Key exclusion criteria:

1. Any disorder/condition, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
2. Known history of histamine intolerance or severe anaphylactic reactions
3. Abnormal values at screening for any of the following laboratory parameters

   * Aspartate aminotransferase (AST) greater than Upper limit of normal (ULN)+10%.
   * Alanine aminotransferase (ALT) greater than ULN +10%.
   * Bilirubin (except if known Gilbert's syndrome) greater than ULN +10%.
   * Creatinine greater than ULN.

     a.eGFR below 90 ml/min/1.73m\^2
   * Glycated haemoglobin (HbA1c) greater than or equal to 5.7% (39 mmol/mol).
4. CYP2D6 unknown phenotype

Primary outcomes:
measure: Part A: Number of treatment-emergent adverse events (TEAE)
timeFrame: From pre-dose (day 1) to end of study, Part A (up to day 13)
measure: Part B: Number of treatment-emergent adverse events (TEAE)
timeFrame: From pre-dose (day 1) to end of study, Part B (up to day 26)
measure: Part C: Number of treatment-emergent adverse events (TEAE)
timeFrame: From pre-dose (day 1) to end of study, Part C (up to day 84)
Secondary outcomes:
measure: Part A: AUC0-∞, SD: the area under the NNC0560-0004 plasma concentration-time curve from time 0 to infinity after a single dose
timeFrame: From pre-dose (day 1) to end of study, Part A (up to day 13)
measure: Part A: Cmax, SD: the maximum plasma concentration of NNC0560-0004 after a single dose
timeFrame: From pre-dose (day 1) to end of study, Part A (up to day 13)
measure: Part A: tmax, SD: the time to maximum concentration of NNC0560-0004 after a single dose
timeFrame: From pre-dose (day 1) to end of study, Part A (up to day 13)
measure: Part A:t½, SD: the terminal half-life of NNC0560-0004 after a single dose
timeFrame: From pre-dose (day 1) to end of study, Part A (up to day 13)
measure: Part B: AUC0-24h, MD: the area under the NNC0560-0004 plasma concentration-time curve in the dosing interval after last dosing
timeFrame: From pre-dose on day 14 until end of study, Part B (up to day 26) (24 hours post-dose)
measure: Part B: Cmax, MD: the maximum plasma concentration of NNC0560-0004 after last dosing
timeFrame: From pre-dose on day 14 to end of study, Part B (up to day 26)
measure: Part B:tmax, MD: the time to maximum concentration of NNC0560-0004 after last dosing
timeFrame: From pre-dose on day 14 to end of study, Part B (up to day 26)
measure: Part B:t½, MD: the terminal half-life of NNC0560-0004 after last dosing
timeFrame: From pre-dose on day 14 to end of study, Part B (up to day 26)
measure: Part C: AUC0-∞, SD: the area under the NNC0560-0004 plasma concentration-time curve from time 0 to infinity after a single dose
timeFrame: From pre-dose (day 1) to end of study, Part C (up to day 84)
measure: Part C: Cmax, SD: the maximum plasma concentration of NNC0560-0004 after a single dose
timeFrame: From pre-dose (day 1) to end of study, Part C (up to day 84)
measure: Part C: tmax, SD: the time to maximum concentration of NNC0560-0004 after a single dose
timeFrame: From pre-dose (day 1) to end of study, Part C (up to day 84)
measure: Part C: t½, SD: the terminal half-life of NNC0560-0004 after a single dose
timeFrame: From pre-dose (day 1) to end of study, Part C (up to day 84)
Other outcomes:
Locations:
city: Watford
country: United Kingdom
facility: Northwick Park Hosptial
state: Middlesex
Study officials:
affiliation: Novo Nordisk A/S
name: Clinical Transparency (dept. 2834)
role: STUDY_DIRECTOR
References: